Original Article

Risk Factors for Complications during Outpatient Parenteral Antimicrobial Therapy for Adult Orthopedic and Neurosurgical Infections

Authors: Kimberly K. Felder, MPAS, MCR, Lynn M. Marshall, ScD, Louise E. Vaz, MD, MPH, Penelope D. Barnes, MBBS, PhD

Abstract

Objectives: Outpatient parenteral antimicrobial therapy (OPAT) is an effective way of treating infections, but complications are common. We identified patient characteristics and OPAT treatment factors associated with increased risk of OPAT-related complications.

Methods: We used a retrospective cohort design that assessed 337 adult patients treated with OPAT for orthopedic and neurosurgical infections between August 1, 2008 and May 30, 2010. Independent variables included demographics, infection characteristics, lead time factors, OPAT treatment factors, and comorbid conditions. Multivariable log-binomial regression was used to estimate the risk of OPAT complications.

Results: The mean patient age was 55 years (range 19–87), 86% had an orthopedic infection, and 44% were treated with intravenous vancomycin. OPAT complications were seen in 45% (152/337) of the cohort. Risk ratios for OPAT complications were 1.9 (95% confidence interval 1.4–2.5) in patients having no primary care provider, 1.7 (95% confidence interval 1.3–2.1) for those treated with vancomycin.

Conclusions: Identifying specific patient characteristics and OPAT treatment factors could facilitate OPAT process improvements to reduce the risk of OPAT complications for vulnerable patients.

 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bernard L, El-Hajj Pron B, et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 2001;26:445-451.
 
2. Kunkel MJ. Quality assurance and outcomes in outpatient parenteral antibiotic therapy. Infect Dis Clin North Am 1998;12:1023-1034.
 
3. Nathwani D, Tice A. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother 2002;49:149-154.
 
4. Chapman AL, Dixon S, Andrews D, et al. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 2009;64:1316-1324.
 
5. Dalovisio JR, Juneau J, Baumgarten K, et al. Financial impact of a home intravenous antibiotic program on a medicare managed care program. Clin Infect Dis 2000;30:639-642.
 
6. Mackintosh CL, White HA, Seaton RA. Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. J Antimicrob Chemother 2011;66:408-415.
 
7. Tice A. The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries. Chemotherapy 2001;47(Suppl 1):5-16.
 
8. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003;114:723-728.
 
9. Tice AD, Strait K, Ramey R, et al. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999;29:1394-1399.
 
10. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004;38:1651-1672.
 
11. Chapman AL, Seaton RA, Cooper MA, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 2012;67:1053-1062.
 
12. Marculescu CE, Berbari EF, Cantey JR, et al. Practical considerations in the use of outpatient antimicrobial therapy for musculoskeletal infections. Mayo Clin Proc 2012;87:98-105.
 
13. Gorski LA. Central venous access device associated infections: recommendations for best practice in home infusion therapy. Home Healthc Nurse 2010;28:221-229.
 
14. Infusion Nurses Society. Infusion Nursing Standards of Practice. J Infus Nurs 2006;29(1 Suppl):S1-S92.
 
15. Allison GM, Muldoon EG, Kent DM, et al. Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy. Clin Infect Dis 2014;58:812-819.
 
16. Barr DA, Semple L, Seaton RA. Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2012;31:2611-2619.
 
17. Pulcini C, Couadau T, Bernard E, et al. Adverse effects of parenteral antimicrobial therapy for chronic bone infections. Eur J Clin Microbiol Infect Dis 2008;27:1227-1232.
 
18. Gilchrist M, Franklin BD, Patel JP. An outpatient parenteral antibiotic therapy (OPAT) map to identify risks associated with an OPAT service. J Antimicrob Chemother 2008;62:177-183.
 
19. Matthews PC, Conlon CP, Berendt AR, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother 2007;60:356-362.
 
20. Wynn M, Dalovisio JR, Tice AD, et al. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J 2005;98:590-595.
 
21. Hoffman-Terry ML, Fraimow HS, Fox TR, et al. Adverse effects of outpatient parenteral antibiotic therapy. Am J Med 1999;106:44-49.
 
22. Upton A, Ellis-Pegler RB, Woodhouse A. Outpatient parenteral antimicrobial therapy (OPAT): a review of experience at Auckland Hospital. N Z Med J 2004;117:U1020.
 
23. Chary A, Tice AD, Martinelli LP, et al. Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey. Clin Infect Dis 2006;43:1290-1295.
 
24. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377Y-381.
 
25. MapQuest Maps. Driving directions. http://www.mapquest.com. Accessed October 22, 2015.
 
26. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
 
27. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162:199-200.
 
28. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
 
29. Brooke BS, Stone DH, Cronenwett JL, et al. Early primary care provider follow-up and readmission after high-risk surgery. JAMA Surg 2014;149:821-828.
 
30. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010;303:1716-1722.
 
31. Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: examining the effects of timing of primary care provider follow-up. J Hosp Med 2010;5:392-397.
 
32. Patient Centered Primary Care Home Program. http://www.oregon.gov/oha/pcpch/pages/index.aspx. Accessed September 24, 2014.
 
33. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-327.
 
34. Pritchard L, Baker C, Leggett J, et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010;123:1143-1149.
 
35. Shrestha NK, Mason P, Gordon SM, et al. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study. J Antimicrob Chemother 2014;69:1407-1415.
 
36. Conterno LO, Turchi MD. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2013;9:CD004439.
 
37. Reeves WC, Strine TW, Pratt LA, et al. Mental illness surveillance among adults in the United States. MMWR Surveill Summ 2011;60(Suppl 3):1-29.